|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and noninterest-bearing deposits in other banks | ||||||||||||||||||||
| Due from Federal Reserve Bank (FRB) | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Investment securities (at fair value) | ||||||||||||||||||||
| Available-for-sale (AFS) debt securities net of allowance for credit losses of $0 (amortized cost of $154,517 and $179,753, respectively) | ||||||||||||||||||||
| Taxable AFS Securities | ||||||||||||||||||||
| Tax-exempt municipal bonds | ||||||||||||||||||||
| Total available-for-sale (AFS) debt securities net of allowance for credit losses of $0 (amortized cost of $154,517 and $179,753, respectively) | ||||||||||||||||||||
| Marketable equity securities | ||||||||||||||||||||
| Total investment securities | ||||||||||||||||||||
| Loans and Leases Receivable, Net Amount | ||||||||||||||||||||
| Loans | ||||||||||||||||||||
| Unearned fees and unamortized loan origination costs - net | ||||||||||||||||||||
| Allowance for credit losses - loans | ||||||||||||||||||||
| Net loans | ||||||||||||||||||||
| Premises and equipment - net | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Other real estate owned (“OREO”) | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Deferred tax assets - net | ||||||||||||||||||||
| Cash surrender value of life insurance - net | ||||||||||||||||||||
| Investment in limited partnerships | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities & Shareholders’ Equity | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Deposits | ||||||||||||||||||||
| Noninterest-bearing | ||||||||||||||||||||
| Interest-bearing | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Federal funds purchased and securities sold under agreements to resell | ||||||||||||||||||||
| Short-term borrowings | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Junior subordinated debentures (at fair value) | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders’ Equity | ||||||||||||||||||||
| Common stock, no par value; 20,000,000 shares authorized; issued and outstanding: 17,582,116 at December 31, 2025 and 17,364,894 at December 31, 2024 | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss, net of tax | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities and shareholders’ equity |
Loading...
